5 Best Drug Stocks to Buy According to Analysts

3. Zoetis Inc. (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) is one of the best drug stocks to buy according to analysts. On April 21, Zoetis Inc. (NYSE:ZTS) announced that it is expanding the capabilities of Vetscan OptiCell, which is its cartridge-based, artificial intelligence-powered hematology analyzer. The expansion marks the next step in the platform’s evolution, with the company stating that the update would make Vetscan OptiCell the first point-of-care hematology analyzer to offer cellular hemoglobin concentration mean (CHCM).

In a separate development, Citi initiated coverage of Zoetis Inc. (NYSE:ZTS) with a Buy rating on April 15 and set a price target of $145. The firm also opened an “upside 90-day catalyst watch” on the company, stating that Solensia will return to growth in fiscal 2026. Citi launched the animal health and dental sectors with a “cautiously optimistic” view, stating that it favors the animal health group and believes that the “humanization” pet trend is real and should drive more spending. Zoetis Inc. (NYSE:ZTS) is its top pick. The firm also stated that it sees the weak macro backdrop pressuring the dental sector, and it anticipates a trade-down to lower-cost implants and orthodontics. It added that its top dental pick is Henry Schein.

Zoetis Inc. (NYSE:ZTS) is a global animal health company that focuses on the discovery, development, manufacture, and commercialization of vaccines, medicines, biodevices, genetic tests, diagnostic products, and precision animal health. Its operations are divided into the United States and International segments.